Complex analysis of coagulation tests in patients undergoing the combination of hemostatic and antithrombotic therapy following large joint arthroplasty

Abstract

Aim. To assess the dynamics of coagulation parameters and the influence of its initial values on the development of postoperative thrombohemorrhagic complications in male and female patients undergoing large joint arthroplasty and received combination hemostatic and anticoagulant therapy.

Methods. A retrospective analysis of the medical records (n=253) of patients with arthroplasty, were divided into two groups based on the time differences between prescription of hemostatic and anticoagulation therapy. The first group includes 145 patients (57.31%, 112 women and 33 men) with time differences ≤17 h, and the second group includes 108 patients (42.68%, 78 women and 30 men) with time differences 18–24 h. The dynamics of coagulation test results were analyzed, and the influence of its initial value on the risk of postoperative thrombosis or bleeding was assessed.

Results. Thrombohemorrhagic complications were recorded in 27 (10.67%) patients, of which 22 (81.48%) were observed in group 1. In the first group, thrombosis developed in regimens with tranexamic acid (p=0.038) with 2.2 times higher incidence than in group 2 (p=0.023). The risk of thrombosis of women in the group 1 was increased by an initially low level of international normalized ratio [relative risk (RR) 13.333, p=0.00032] and activated partial thromboplastin time (RR=5.8, p=0.037). The risk of bleeding in group 1 increased by an increasing preoperative ­level of activated partial thromboplastin time (RR=18, p=0.0012 and RR=28, p=0.00022, respectively) for all patients and by a decreasing fibrinogen level (RR=23.25, p=0.00065) and platelets count (RR=10.2, p=0.038) for women.

Conclusion. To minimize the risks of thrombosis and bleeding after arthroplasty, especially in patients with initial deviations of hemostasis parameters from the norm, and, in particular, when using tranexamic acid as a hemosta­tic agent, it is recommended to observe the time interval between hemostatic and anticoagulant pharmacothe­rapy for at least 18 hours.

Keywords

hrombosis / bleeding / endoprosthetics / coagulogram / time interval / anticoagulants / hemostatic agents

References

[1] Leitner L., Türk S., Heidinger M. et al. Trends and economic impact of hip and knee arthroplasty in Central Europe: Findings from the Austrian National Database. Sci. Reports. 2018; 8 (1): 4707. DOI: 10.1038/s41598-018-23266-w.

[2] Veber E.V., Vorontsova T.N., Bogopolskaya A.S., Bezgodkov Yu.A. Routing of adult patients with pathology of hip and knee joints. Sovremennye problemy nauki i obrazovaniya. 2017; (2): 94. (In Russ.)

[3] Вебер Е.В., Воронцова Т.Н., Богопольская А.С., Безгодков Ю.А. Маршрутизация взрослых пациентов с патологией тазобедренного и коленного суставов. Соврем. пробл. науки и образования. 2017; (2): 94.

[4] Oremus K. Tranexamic acid for the reduction of blood loss in total knee arthroplasty. Ann. Transl. Med. 2015; 3 (1): 40. DOI: 10.3978/j.issn.2305-5839.2015.03.35.

[5] Novikov A.V., Shchedrina M.A., Karataeva D.S., Martyanov A.S. Early rehabilitation of elderly patients following knee arthroplasty. Trudnyy patsient. 2018; 16 (6): 42–45. (In Russ.)

[6] Новиков А.В., Щедрина М.А., Каратаева Д.С., Мартьянов А.С. Особенности ранней реабилитации больных пожилого возраста после эндопротезирования коленного сустава. Трудный пациент. 2018; 16 (6): 42–45.

[7] Nikolaev N.S., Bezlyud­naya N.V., Didichenko S.N., Kadyrova L.R. Experience of endoprothetics of joints and recommendations for perio­perative management. Prakticheskaya meditsina. 2014; (5): 92–96. (In Russ.)

[8] Николаев Н.С., Безлюдная Н.В., Дидиченко С.Н., Кадырова Л.Р. Опыт эндопротезирования суставов и рекомендации по периоперационному ведению. Практич. мед. 2014; (5): 92–96.

[9] Bozhkova S.A., Kasimova A.R., Nakopia V.B., Kornilov N.N. Do we know all about prevention of venous thromboembolism after major orthopedic surgery? Travmatologiya i ortopediya Rossii. 2018; 24 (1): 129–143. (In Russ.) DOI: 10.21823/2311-2905-2018-24-1-129-143.

[10] Божкова С.А., Касимова А.Р., Накопия В.Б., Корнилов Н.Н. Всё ли мы знаем о профилактике венозных тромбоэмболических осложнений после больших ортопедических операций? Травматология и ортопедия России. 2018; 24 (1): 129–143. DOI: 10.21823/2311-2905-2018-24-1-129-143.

[11] Ershov D.S., Kopenkin S.S., Skoroglyadov A.V. Prophylaxis and treatment of deep vein thrombosis of lower extremities at total hip replacement: a literature review. Vestnik Rossyskogo gosudarstvennogo meditsinskogo universiteta. 2015; (3): 14–19. (In Russ.)

[12] Ершов Д.С., Копёнкин С.С., Скороглядов А.В. Профилактика и лечение тромбозов глубоких вен нижних конечностей при эндопротезировании тазобедренного сустава (обзор литературы). Вестн. Рос. гос. мед. ун-та. 2015; (3): 14–19.

[13] Ziatdinov B.G., Akhtyamov I.F., Sadykov R.I. Modern facilities of thromboembolic complications prevention at the replacement of lower extremities large joints. Prakticheskaya meditsina. 2015; (4-1): 66–70. (In Russ.)

[14] Зиатдинов Б.Г., Ахтямов И.Ф., Садыков Р.И. Современные возможности профилактики тромбоэмболических осложнений при эндопротезировании крупных суставов нижних конечностей. Практич. мед. 2015; (4-1): 66–70.

[15] Nakopiya V.B., Kornilov N.N., Bozhkova S.A. et al. Hidden blood loss after total knee arthroplasty with complex thromboprophylaxis. Sovremennye problemy nauki i obrazovaniya. 2017; (6): 97. (In Russ.) DOI: 10.17513/spno.27272.

[16] Накопия В.Б., Корнилов Н.Н., Божкова С.А. и др. Скрытая кровопотеря после тотального эндопротезирования коленного сустава на фоне комплексной антикоагулянтной тромбопрофилактики. Соврем. пробл. науки и образования. 2017; (6): 97. DOI: 10.17513/spno.27272.

[17] Huang F., Wu Y., Yin Z. et al. A systematic review and meta-analysis of the use of antifibrinolytic agents in total hip arthroplasty. Hip. Int. 2015; 25 (6): 502–509. DOI: 10.5301/hipint.5000285.

[18] Dobrovol'skiy F. Expedience of the prophylactic use of tranexamic acid in surgical practice. Vestnik eks­trennoy meditsiny. 2017; (3): 83–87. (In Russ.)

[19] Добровольский Ф. Целесообразность профилактического применения транексамовой кислоты в хирургической практике. Вестн. экстренной мед. 2017; (3): 83–87.

[20] Kapadia B.H., Torre B.B., Ullman N. et al. Redu­cing perioperative blood loss with antifibrinolytics and antifibrinolytic-like agents for patients undergoing total hip and total knee arthroplasty. J. Orthop. 2019; 16 (6): 513–516. DOI: 10.1016/j.jor.2019.06.025.

[21] Register of medicines of Russia. Encyclopedia of drugs. https://www.rlsnet.ru/mnn_index_id_1290.htm (access date: 19.03.2020). (In Russ.)

[22] Регистр лекарственных средств. Энциклопедия лекарств. https://www.rlsnet.ru/mnn_index_id_1290.htm (дата обращения: 19.03.2020).

[23] Fraval A., Duncan S., Murray T. et al. OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. HIP International. 2019; 29 (3): 239–244. DOI: 10.1177/1120700018780125.

[24] Hourlier H., Fennema P. Tranexamic acid use and risk of thrombosis in regular users of antithrombotics undergoing primary total knee arthroplasty: a prospective cohort study. Blood Transfus. 2018; 16 (1): 44–52. DOI: 10.2450/2016.0160-16.

[25] Wang J.W., Chen B., Lin P.C. et al. The efficacy of combined use of Rivaroxaban and Tranexamic acid on blood conservation in minimally invasive total knee arthroplasty: a double-blind randomized, controlled ­trial. J. Arthroplasty. 2017; 32 (3): 801–806. DOI: 10.1016/j.arth.2016.08.020.

[26] Karampinas P.K., Megaloikonomos P.D., Lampropoulou-Adamidou K. et al. Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-­articular and intravenous tranexamic acid in total knee arthroplasty. Eur. J. Orthop. Surg. Traumatol. 2019; 29: 455–460. DOI: 10.1007/s00590-018-2307-7.

[27] Russian clini­cal guidelines “Prevention of Venous Thromboembolic Complications”. Travmatologiya i ortopediya Rossii. 2012; 1 (suppl.): 1–24. (In Russ.)

[28] Российские клинические рекомендации «Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии». Травматология и ортопедия России. 2012; 1 (прил.): 1–24.

[29] Russian clinical guidelines for the diagnosis, treatment and prevention of Venous Thromboembolic Complications (VTE). Flebologiya. 2015; 9 (4-2): 1–52 (In Russ.)

[30] Российские клинические рекомендации по диагностике, лечению и профилактике ВТЭО. Флебология. 2015; 9 (4-2): 1–52.

[31] Antropova I.P., Shlykov I.L., Kuznetsova N.L. Hemostasis system after the knee endoprosthetics under antithrombotic prevention by Dabigatran direct thrombin inhibitor. Geniy ortopedii. 2011; (4): 90–96. (In Russ.)

[32] Антропова И.П., Шлыков И.Л., Кузнецова Н.Л. Система гемостаза после эндопротезирования коленного сустава при антитромботической профилактике прямым ингибитором тромбина дабигатраном. Гений ортопедии. 2011; (4): 90–96.

[33] Golovko L.S., Safronenko A.V., Gantsgorn E.V., Sukhorukova N.V. Thrombohemorrhagic complications among patients after knee and hip arthroplasty on the background of joint therapy with hemostatic and anticoa­gulants. Uralskiy meditsinskiy zhurnal. 2020; (1): 47–52. (In Russ.) DOI: 10.25694/URMJ.2020.01.09.

[34] Головко Л.С., Сафроненко А.В., Ганцгорн Е.В., Сухорукова Н.В. Тромбогеморрагические осложнения у пациентов после эндопротезирования коленных и тазобедренных суставов на фоне совместной терапии гемостатиками и антикоагулянтами. Уральский мед. ж. 2020; (1): 47–52. DOI: 10.25694/URMJ.2020.01.09.

RIGHTS & PERMISSIONS

Golovko L.S., Safronenko A.V., Gantsgorn E.V., Sukhorukova N.V., Maklyakov Y.S.